Skip to main
ALEC
ALEC logo

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Alector Inc exhibits a promising outlook due to its innovative therapeutic approach targeting neurodegeneration, particularly through its differentiated transferrin receptor (TfR) binding technology, which has shown significantly enhanced brain uptake in non-human primates (NHPs). The company’s pipeline, which includes late-stage programs like AL137, AL050, and ADP064-ABC, represents substantial potential given the larger indications they target, suggesting that positive clinical data could yield considerable upside for investors. Furthermore, the company’s commitment to utilizing standardized Alzheimer’s disease biomarkers enhances the likelihood of demonstrating clinically meaningful results, bolstering confidence in the overall efficacy of Alector’s therapies.

Bears say

Alector Inc's recent downgrade to Neutral is largely attributed to the failure of the INFRONT-3 trial for latozinemab, which did not meet its primary endpoint and raises significant translational biology risks. Additional concerns stem from potential failures in their pipeline products, AL001 and AL002, regarding both regulatory approval and their ability to achieve projected peak commercial revenues, compounded by risks of negative trial results or unexpected toxicities. The company’s reliance on biomarker modulation without a demonstrated clinical impact in current trials further underscores the uncertainties surrounding its therapeutic approaches, which contributes to a negative financial outlook.

Alector Inc (ALEC) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 5 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.